ArticleNature communications2023
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Enhanced efficacy of lung cancer treatment with radiotherapy and immune checkpoint inhibitors without increased pneumonia risk: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.Nature cancer · 2025Trial
- Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.Oncoimmunology · 2026Review
- Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.Bioactive materials · 2026Article
- Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.Medical oncology (Northwood, London, England) · 2026Review
- Thieno[3,2-International journal of molecular sciences · 2026Review
- Comparative Evaluation of Plant-Derived Virus-like Particles as Intratumoral Immunotherapy Agents.Vaccines · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.Cell death and differentiation · 2026Article
- CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy.Cell reports. Medicine · 2026Article
- NK cell-derived GZMB (granzyme B) suppresses glioblastoma radioresistance by blocking SDC1-mediated autophagosome maturation.Autophagy · 2026Article
- Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Review
- The tumor microenvironment as a key regulator of radiotherapy response.Frontiers in immunology · 2026Review
- FLASH radiotherapy as an emerging paradigm in radioimmunotherapy: biological rationale, preclinical evidence, and translational roadmap.Frontiers in immunology · 2026Review
- Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse model.Frontiers in immunology · 2026Article
- Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7Oncoimmunology · 2025Article
- 2240 nm NIR-IV Photodynamic Therapy Can Reverse Ineffective Anti-OX40 Cancer Immunotherapy to Become Effective.ACS nano · 2025Article
- Prognostic value of tumor-infiltrating lymphocytes in irradiated node-positive breast cancer patients.Breast (Edinburgh, Scotland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Radiation therapy (RT) increases tumor response to CTLA-4 inhibition (CTLA4i) in mice and in some patients, yet deep responses are rare. To identify rational combinations of immunotherapy to improve responses we use models of triple negative breast cancer highly resistant to immunotherapy in female mice. We find that CTLA4i promotes the expansion of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.